Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
N-{2-methyl-5-[(6-phenylpyrimidin-4-yl)amino]phenyl}methanesulfonamide is a synthetic small molecule belonging to the phenylpyrimidine class. It is characterized by a sulfonamide group and a pyrimidine ring substituted with a phenyl group. The compound has been identified as an inhibitor of β-secretase 1 (BACE1), an enzyme involved in the cleavage of amyloid precursor protein, which is relevant to Alzheimer's disease pathology. Its primary research interest lies in its potential as an anti-Alzheimer's agent, though it also exhibits antimicrobial and anti-inflammatory properties[9]. There are no known approved therapeutic uses or marketed formulations for this compound.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on N-{2-methyl-5-[(6-phenylpyrimidin-4-yl)amino]phenyl}methanesulfonamide.